Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer

Abstract

Individuals diagnosed with metastatic triple-negative breast cancer (mTNBC) suffer worse survival rates than their metastatic non-TNBC counterparts. There is little information on survival, treatment patterns, and medical costs of mTNBC patients in Asia. Therefore, this study aimed to examine 5-year survival, regimens of first-line systemic therapy, and healthcare costs of mTNBC patients in Taiwan. Adult females newly diagnosed with TNBC and non-TNBC as well as their survival data, treatment regimens and costs of health services were identified and retrieved from the Cancer Registry database, Death Registry database, and National Health Insurance (NHI) claims database. A total of 9691 (19.27%) women were identified as TNBC among overall BC. The 5-year overall survival rate of TNBC and non-TNBC was 81.28% and 86.50%, respectively, and that of mTNBC and metastatic non-TNBC was 10.81% and 33.46%, respectively. The majority of mTNBC patients received combination therapy as their first-line treatment (78.14%). The 5-year total cost in patients with metastatic non-TNBC and with mTNBC was NTD1,808,693 and NTD803,445, respectively. Higher CCI scores were associated with an increased risk of death and lower probability of receiving combination chemotherapy. Older age was associated with lower 5-year medical costs. In sum, mTNBC patients suffered from poorer survival and incurred lower medical costs than their metastatic non-TNBC counterparts. Future research will be needed when there are more treatment options available for mTNBC patients.

A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments

“…25 In Western countries (United States, Canada and Germany) 65-67% of mTNBC patients receive monotherapy as their first-line treatment rather than combination regimens, which are more popular in Asia. 26 However, the overall efficacy of both monotherapy and combined chemotherapy for the treatment of mTNBC is limited. A meta-analysis of mTNBC subgroups from three Phase III first-line trials reported a pooled median ORR of 23%, OS of 17.5 months and median PFS of 5.4 months with single-agent chemotherapy.…”

Mining TCGA Database for Genes with Prognostic Value in Breast Cancer

“…A lack of predictive value for the HER2 enriched subtype in presented results could therefore stem from the relatively low number of identified cases with this subtype ( n = 15; 5% of all tumors). Triple negative breast cancers (TNBC) are known to lead to a poor prognosis, with reported overall 5-year survival rates between 62% and 82%, compared to 75% to 86% in the case of non-TNBC patients [ 54 , 55 ]. Our results agree with the survival rates of TNBC patients, the data analyzed here yielding a 5-year survival rate of 61% ( Supplementary Figure S1C ).…”

Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer

“…TNBC patients have a very poor prognosis overall, and survival rarely extends beyond 12 months from the time of recurrence. The 5-year overall survival rate in metastatic TNBC (mTNBC) patients is 4–20%, much worse than the other types of breast cancer [ 3 , 4 ].…”